## **AMENDMENTS TO THE CLAIMS**

## 1-37. (**Canceled**)

- 38. (New) A method of treating cancer in a subject, comprising topically administering to a subject in need thereof a composition comprising a therapeutically effective amount of between about 0.01% and 30% w/w of Coenzyme Q10, thereby treating cancer in the subject.
- 39. (New) A method of treating cancer in a subject, comprising topically administering to a subject in need thereof a composition comprising an effective amount of between about 1.5 and 4.0 mg of Coenzyme Q10 per kg of body weight of the subject, thereby treating cancer in the subject.
- 40. (New) The method of claim 38 or 39, wherein the subject is human.
- 41. **(New)** The method of claim 38 or 39, wherein the composition comprising Coenzyme Q10 is formulated as a topical cream.
- 42. **(New)** The method of claim 38 or 39, wherein the composition comprising Coenzyme Q10 is liposomal.
- 43. **(New)** The method of claim 38, wherein the composition comprises about 1% to about 25% w/w of Coenzyme Q10.
- 44. **(New)** The method of claim 38, wherein the composition comprises about 1% to about 20% w/w of Coenzyme Q10.
- 45. **(New)** The method of claim 38 or 39, wherein the cancer is selected from the group consisting of a melanoma, carcinoma, sarcoma, leukemia and lymphoma.
- 46. (New) The method of claim 38 or 39, wherein the cancer is a melanoma.

- 47. (New) The method of claim 38 or 39, wherein the cancer is a carcinoma.
- 48. (New) The method of claim 47, wherein the carcinoma is squamous cell carcinoma.
- 49. (New) The method of claim 47, wherein the carcinoma is breast adenocarcinoma.
- 50. (New) The method of claim 47, wherein the carcinoma is hepatocellular carcinoma.
- 51. (New) The method of claim 47, wherein the carcinoma is prostatic adenocarcinoma.
- 52. (New) The method of claim 38 or 39, wherein the cancer is a sarcoma.
- 53. (New) The method of claim 52, wherein the sarcoma is an osteosarcoma.
- 54. (New) The method of claim 38 or 39, wherein the cancer is selected from the group consisting of skin cancer, breast cancer, prostate cancer, liver cancer and bone cancer.
- 55. (New) The method of claim 54, wherein the cancer is skin cancer.
- 56. (New) The method of claim 54, wherein the cancer is breast cancer.
- 57. (New) The method of claim 54, wherein the cancer is prostate cancer.
- 58. (New) The method of claim 54, wherein the cancer is liver cancer.
- 59. (New) The method of claim 52, wherein the cancer is bone cancer.
- 60. **(New)** The method of claim 38 or 39, wherein the composition comprising Coenzyme Q10 is administered with an additional anti-cancer agent.
- 61. (New) The method of claim 60, wherein the additional anti-cancer agent is a chemotherapeutic agent.

62. (New) The method of claim 61, wherein the chemotherapeutic agent is selected from the group consisting of cyclophosphamide, taxanes, busulfan, methotrexate, daunorubicin, doxorubicin, melphalan and cladribine.

- 63. (New) The method of claim 61, wherein the chemotherapeutic agent is selected from the group consisting of vincristine, vinblastine, chlorambucil, tamoxifen, taxol, camptothecin, actinomycin-D, mitomycin C and combretastatin.
- 64. (New) The method of claim 61, wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, etoposide, adriamycin, verapamil and podophyllotoxin.
- 65. (New) The method of claim 61, wherein the chemotherapeutic agent is 5-fluorouracil.
- 66. (New) The method of claim 60, wherein the additional agent is an anti-angiogenic agent.
- 67. (New) The method of claim 60, wherein the additional anti-cancer agent is coadministered with the composition comprising Coenzyme Q10 to the subject.
- 68. (New) The method of claim 60, wherein administration of the additional anti-cancer agent precedes administration of the composition comprising Coenzyme Q10 to the subject.
- 69. (New) The method of claim 60, wherein administration of the additional anti-cancer agent follows administration of the composition comprising Coenzyme Q10 to the subject.
- 70. (New) The method of claim 38 or 39, wherein treatment results in inhibition of tumor cell growth in the subject.
- 71. (New) The method of claim 38 or 39, wherein treatment results in an increase in apoptosis of tumor cells in the subject.
- 72. **(New)** The method of claim 38 or 39, wherein treatment results in inhibition of tumor-mediated angiogenesis in the subject.

73. (New) A method for inhibiting tumor cell growth in a subject, the method comprising topically administering to a subject having a tumor a pharmaceutical composition comprising Coenzyme Q10, thereby inhibiting tumor cell growth in the subject.

- 74. (New) The method of claim 73, wherein the subject is human.
- 75. **(New)** The method of claim 73, wherein the pharmaceutical composition comprising Coenzyme Q10 is formulated as a topical cream.
- 76. (New) The method of claim 73, wherein the pharmaceutical composition comprising Coenzyme Q10 is liposomal.
- 77. **(New)** The method of claim 73, wherein the pharmaceutical composition comprises about 0.01% to about 30% w/w of Coenzyme Q10.
- 78. **(New)** The method of claim 73, wherein the pharmaceutical composition comprises about 1% to about 25% w/w of Coenzyme Q10.
- 79. **(New)** The method of claim 73, wherein the pharmaceutical composition comprises about 1% to about 20% w/w of Coenzyme Q10.
- 80. (New) A method of inducing apoptosis in a tumor cell in a subject, the method comprising topically administering to a subject having a tumor a pharmaceutical composition comprising Coenzyme Q10, thereby inducing apoptosis in a tumor cell in the subject.
- 81. (New) The method of claim 80, wherein the subject is human.
- 82. (New) The method of claim 80, wherein the pharmaceutical composition induces apoptosis in at least about 30% of tumor cells.
- 83. (New) The method of claim 80, wherein the pharmaceutical composition induces apoptosis in about 50% of tumor cells.

84. **(New)** The method of claim 80, wherein the pharmaceutical composition induces apoptosis in about 60% of tumor cells.

- 85. (New) The method of claim 80, wherein the pharmaceutical composition induces apoptosis in about 75% of tumor cells.
- 86. (New) The method of claim 80, wherein the pharmaceutical composition induces apoptosis in about 90% of tumor cells.
- 87. **(New)** The method of claim 80, wherein the pharmaceutical composition induces apoptosis in about 99.9% of tumor cells.
- 88. **(New)** The method of claim 80, wherein the pharmaceutical composition comprising Coenzyme Q10 is formulated as a topical cream.
- 89. **(New)** The method of claim 80, wherein the pharmaceutical composition comprising Coenzyme Q10 is liposomal.
- 90. **(New)** The method of claim 80, wherein the pharmaceutical composition comprises about 0.01% to about 30% w/w of Coenzyme Q10.
- 91. **(New)** The method of claim 80, wherein the pharmaceutical composition comprises about 1% to about 25% w/w of Coenzyme Q10.
- 92. (New) The method of claim 80, wherein the pharmaceutical composition comprises about 1% to about 20% w/w of Coenzyme Q10.
- 93. (New) A method of inhibiting tumor mediated angiogenesis in a subject, the method comprising topically administering to a subject having a tumor a pharmaceutical composition comprising Coenzyme Q10, thereby inhibiting tumor mediated angiogenesis in a subject.
- 94. (New) The method of claim 93, wherein the subject is human.

95. **(New)** The method of claim 93, wherein the pharmaceutical composition comprising Coenzyme Q10 is formulated as a topical cream.

- 96. (New) The method of claim 93, wherein the pharmaceutical composition comprising Coenzyme Q10 is liposomal.
- 97. **(New)** The method of claim 93, wherein the pharmaceutical composition comprises about 0.01% to about 30% w/w of Coenzyme Q10.
- 98. (New) The method of claim 93, wherein the pharmaceutical composition comprises about 1% to about 25% w/w of Coenzyme Q10.
- 99. (New) The method of claim 93, wherein the pharmaceutical composition comprises about 1% to about 20% w/w of Coenzyme Q10.